Cat. No.: HY-131454

SR-717

34 Cited Publications

Customer Review

Based on 34 publication(s) in Google Scholar

SR-717 is a non-nucleotide STING agonist with EC₅₀s of 2.1 μM and 2.2 μM in ISG-THP1 (WT) and ISG-THP1 cGAS KO (cGAS KO) cell lines, respectively. SR-717 is a stable cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) mimetic. Antitumor activity.

For research use only. We do not sell to patients.

Purity: 99.79%
CAS No.: 2375421-09-1
Formula: C₁₅H₈F₂LiN₅O₃
Molecular Weight:351.19

Storage:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)

SR-717 Chemical Structure

CAS No.: 2375421-09-1

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
- In Vivo
Chemical Information
Publications (34)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

In Vitro

SR-717 activates STING by inducing the same closed conformation, which thereby provides an avenue to explore this class of systemic STING agonist in diverse contexts, including antitumor immunity^[1].
SR-717 (3.8 μM) induces the expression of PD-L1 in THP1 cells and in primary human peripheral blood mononuclear cells in a STING-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

SR-717 (30 mg/kg intraperitoneal once-per-day for 1 week) shows antitumor activities in WT or Sting^gt/gt mice^[1].
SR-717 (30 mg/kg intraperitoneally for 7 days) displays antitumor activity; promots the activation of CD8⁺ T, natural killer, and dendritic cells in relevant tissues; and facilitates antigen cross-priming^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

WT or Sting^gt/gt mice^[1]
Dosage:

30 mg/kg
Administration:

Intraperitoneally; once-per-day for 1 week
Result:

Maximally inhibited tumor growth.

Chemical Information

CAS No. 2375421-09-1
Appearance Solid
Molecular Weight 351.19
Formula C₁₅H₈F₂LiN₅O₃
Color White to off-white
SMILES

O=C(O[Li])C1=CC(F)=C(F)C=C1NC(C2=NN=C(N3C=CN=C3)C=C2)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)

Publications (34)

All Cell Proliferation/Viability AssayFlow CytometryRT-PCRWBIF

Sort by:

Journal Impact Factor

Immunity

A chemical agonist and the Golgi-resident lipid PI4P activate STING by inducing transmembrane helix rearrangement. [Abstract]

2025 Dec 5:S1074-7613(25)00506-0. PMID: 41352342
Nat Commun

Transferrin-phosphatidylserine liposomes target TDP-43 and neuroinflammation in male mice with neuropathic pain. [Abstract]

2025 Dec 12;16(1):11314. PMID: 41387431

SR-717 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Dec 12;16(1):11314. [Abstract]

CCK8 assays revealed that SR717 significantly reversed the increase in cell viability induced by TF/PS/TDP-43-IN-1 in primary astrocytes and microglia.

SR-717 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Dec 12;16(1):11314. [Abstract]

Western blot analysis showed SR717 reduced expression of C3 and S100A10 in astrocytes and decreased CD86 and CD206 levels in microglia after treatment, indicating reversal of inflammatory phenotypes.

SR-717 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Dec 12;16(1):11314. [Abstract]

Immunofluorescence SR717 reversed the C3 and S100A10 expression changes in injured primary astrocytes and CD86 and CD206 expression in microglia induced by TF/PS/TDP-43-IN-1.
Nat Commun

Cholesterol removal improves performance of a model biomimetic system to co-deliver a photothermal agent and a STING agonist for cancer immunotherapy. [Abstract]

2023 Aug 22;14(1):5111. PMID: 37607938

SR-717 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 Aug 22;14(1):5111. [Abstract]

SR-717 (10 mg/kg, i.v.) increased PD-L1 expression on tumor cells by flow cytometry.
J Clin Invest

Polyamine sequestration of 2'3'-cGAMP constrains intercellular transmission and STING engagement to subvert antitumor immunity. [Abstract]

2026 Jun 1;136(11):e201460. PMID: 42222888
Adv Sci (Weinh)

Ginkgetin Alleviates Inflammation and Senescence by Targeting STING. [Abstract]

2025 Jan;12(2):e2407222. PMID: 39558862
Cell Death Differ

Activating STING/TBK1 suppresses tumor growth via degrading HPV16/18 E7 oncoproteins in cervical cancer. [Abstract]

2024 Jan;31(1):78-89. PMID: 38007552
Chem Eng J

2025 May 1.
J Control Release

Protein corona-guided delivery of dextran-PLGA NPs for enhanced dendritic cell uptake, maturation and improved cancer immunotherapy. [Abstract]

2026 Feb 15:392:114733. PMID: 41702510
Cancer Biol Med

Antitumor effects of STING agonists on nervous system tumors via tumor-intrinsic STING-STAT1-mediated HMGN2 expression. [Abstract]

2026 Feb 16;23(1):133-153. PMID: 41700809
Phytomedicine

Chlorogenic acid targets STING to alleviate pressure overload-induced heart failure and myocardial fibrosis. [Abstract]

2026 Jan:150:157625. PMID: 41338109
Acta Pharmacol Sin

Zinc pyrithione functions as a small-molecule STING agonist to exert antitumor immunotherapy effects. [Abstract]

2025 Oct 17. PMID: 41107405
Sci China Life Sci

Targeting STING oligomerization with licochalcone D ameliorates STING-driven inflammatory diseases. [Abstract]

2024 Dec;67(12):2664-2677. PMID: 39190126
Free Radic Biol Med

2025 Oct 25.
ACS Appl Mater Interfaces

Ultrasound-Responsive Cerasome Nanoparticle Improves STING-Driven Immunotherapy in Triple-Negative Breast Cancer. [Abstract]

2026 Feb 18;18(6):9379-9400. PMID: 41660697
Am J Chin Med

Apigenin Suppresses Innate Immune Responses and Ameliorates Lipopolysaccharide-Induced Inflammation via Inhibition of STING/IRF3 Pathway. [Abstract]

2024;52(2):471-492. PMID: 38480499
Clin Sci

Flavonoid Derivative DMXAA Attenuates Cisplatin-induced Acute Kidney Injury Independent of STING Signaling. [Abstract]

2023 Mar 31;137(6):435-452. PMID: 36815438
Antioxid Redox Signal

Endothelial Gasdermin D Induces Mitochondrial Damage and Activates the STING Pathway in Lipopolysaccharide-Accelerated Atherosclerosis. [Abstract]

2025 Sep 29. PMID: 41017337

SR-717 purchased from MedChemExpress. Usage Cited in: Antioxid Redox Signal. 2025 Sep 29. [Abstract]

SR-717 (10 mg/kg, i.p.) increased the mRNA expression levels of IL-1β, IL-6, IL-18, and MCP-1 mRNA levels as determined by qPCR.
Biochem Pharmacol

Activation of the Nrf2/HO-1/GPX4 pathway by cGAMP Mitigates oxidative stress and ferroptosis in ischaemic stroke. [Abstract]

2025 Sep 14;242(Pt 2):117334. PMID: 40957492
Biochem Pharmacol

STING activation in macrophages by vanillic acid exhibits antineoplastic potential. [Abstract]

2023 Jul:213:115618. PMID: 37211172
Cell Insight

IRF1 amplifies HSV-1-triggered antiviral innate immunity in a feed-forward manner. [Abstract]

2025 May 22;4(4):100255. PMID: 40586041
Int J Pharm

Enhancement of cancer immunotherapy using CRT valgus tumor cell membranes coated bacterial whole peptidoglycan combined with radiotherapy. [Abstract]

2023 Nov 5:646:123430. PMID: 37742823
Cell Rep Methods

A fluorescent STING ligand sensor for high-throughput screening of compounds that can enhance tumor immunotherapy. [Abstract]

2025 Jul 21;5(7):101106. PMID: 40669456
Eur J Pharmacol

Pharmacological targeting of cGAS/STING-YAP axis suppresses pathological angiogenesis and ameliorates organ fibrosis. [Abstract]

2022 Oct 15:932:175241. PMID: 36058291
Int Immunopharmacol

Corilagin inhibits human cytomegalovirus infection and replication via activating the cGAS-STING signaling pathway in vitro and in vivo. [Abstract]

2024 Oct 17;143(Pt 2):113401. PMID: 39423664
Cell Signal

2026 Mar 6.
iScience

Detection of nuclear STING in cultured human cells and in the normal and cancer tissues. [Abstract]

2026 Apr 10;29(5):115711. PMID: 42095073
Biomedicines

GSDME in Endothelial Cells: Inducing Vascular Inflammation and Atherosclerosis via Mitochondrial Damage and STING Pathway Activation. [Abstract]

2023 Sep 20;11(9):2579. PMID: 37761020
FASEB J

Osteoclastogenesis Responds to STING Inhibition in a Non-Monotonic Manner. [Abstract]

2026 Mar 31;40(6):e71596. PMID: 41830493
Fish Shellfish Immunol

ISGylation of zebrafish STING at lysines 221 and 276 activates innate immunity. [Abstract]

2025 Nov:166:110640. PMID: 40780681
J Integr Neurosci

Inhibition of cGAS Reduces Brain Injury and Facilitates Neurological Recovery via the STING-Mediated Signaling Pathway After Germinal Matrix Hemorrhage in Neonatal Mice. [Abstract]

2025 Aug 22;24(8):39286. PMID: 40919625
SSRN

2026 Apr 7.
SSRN

2026 Mar 23.
Sci Total Environ

Mitochondrial DNA release mediated by TFAM deficiency promotes copper-induced mitochondrial innate immune response via cGAS-STING signalling in chicken hepatocytes. [Abstract]

2023 Dec 20:905:167315. PMID: 37742962
Research Square Print

2023 Feb 2.

Solvent & Solubility

In Vitro:

DMSO : 10 mg/mL (28.47 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Methanol : 3.33 mg/mL (9.48 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.8475 mL

14.2373 mL

28.4746 mL

5 mM

0.5695 mL

2.8475 mL

5.6949 mL

10 mM

0.2847 mL

1.4237 mL

2.8475 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1 mg/mL (2.85 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1 mg/mL (2.85 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1 mg/mL (2.85 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 10 mg/mL (28.47 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Emily N Chin, et al. Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic. Science. 2020 Aug 21;369(6506):993-999. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
Methanol / DMSO	1 mM	2.8475 mL	14.2373 mL	28.4746 mL	71.1865 mL
Methanol / DMSO	5 mM	0.5695 mL	2.8475 mL	5.6949 mL	14.2373 mL
DMSO	10 mM	0.2847 mL	1.4237 mL	2.8475 mL	7.1187 mL
	15 mM	0.1898 mL	0.9492 mL	1.8983 mL	4.7458 mL
	20 mM	0.1424 mL	0.7119 mL	1.4237 mL	3.5593 mL
	25 mM	0.1139 mL	0.5695 mL	1.1390 mL	2.8475 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

SR-717

Immunology/Inflammation Compound Library

Anti-Cancer Compound Library

Small Molecule Immuno-Oncology Compound Library

Immunopotentiator Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) SR-717

Biological Activity

Chemical Information

Publications (34)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

SR-717

Immunology/Inflammation Compound Library

Anti-Cancer Compound Library

Small Molecule Immuno-Oncology Compound Library

Immunopotentiator Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) SR-717

Biological Activity

Chemical Information

Publications (34)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

SR-717 Related Classifications

HY-131454 Related Classifications